Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multinational, randomized Phase 2 study confirming the clinical
benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in
previously treated CCA harboring FGFR2 gene fusions and other rearrangements.